ABSTRACT
Management of various secondary immunodeficiencies includes passive immunotherapy with IVIG. One of the most prominent conditions is immunodeficiency in allogeneic bone marrow transplant (BMT) recipients. A number of studies were devoted to the assessment of phannacokinetics of IVIG and IgG antibodies in BMT patients. Results of T 112 detenninations were conflicting since various investigators observed surprisingly short values whereas others reported survival times comparable with those found in patients with congenital humoral immunodeficiency or in nonnal subjects. Some of these studies are briefly summarized here and results are presented in Table 6 (42-49).
